SHORT TERM TREATMENT OF CHRONIC HYPERKALEMIA WITH ORAL POTASSIUM BINDER IN CHRONIC KIDNEY DISEASE PATIENTS

  • Sabir Sulejman Clinic of Nephrology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Angela Karanfilovik Clinic of Nephrology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Ana Stojanoska Clinic of Nephrology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Mimoza Milenkova Clinic of Nephrology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Julijana Usprcov Clinic of Nephrology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Bleron Kolonja Specialized Hospital of Nephrology, Struga,North Macedonia
  • Izet Salkoski Specialized Hospital of Nephrology, Struga, North Macedonia
  • Hristina Minovska Department of Internal Medicine, Clinic hospital Dr. Trifun Panovski Bitola, North Macedonia
  • Adrian Memeti Clinic of Nephrology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Adrijana Spasovska Clinic of Nephrology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Oliver Ristevski Department of Internal Medicine, General City Hospital , Skopje, North Macedonia

Abstract

The aim of our study was to analyse the efficacy of short-term administration of oral calcium polystyrene sulfonate (CPS) to treat hyperkalemia in non-dialysis CKD patients. A prospective interventional study was conducted in 65 CKD patients with chronic hyperkalemia with a month of therapy. Patients were stratified into groups in respect of potassium level (mild <5.9; moderate 6-6.5; severe ≥6.5 mmol/l). Regression analysis was applied to investigate associations of hyperkalemia with different variables. Paired T-Test was used for comparative analysis of potassium levels before and after therapy. Patients mean age was 67 years, eGFR ranged between 8 to 52ml/min. More than half of patients presented with moderate or severe hyperkalemia.None of the demographic, clinical or pharmacological variables predicted potassium level. The comparative analysis with paired samples T-Test showed significantly lower potassium levels after one month of therapy (p<0.001). The portion of patients that were encountered for mild hyperkalemia significantly increased (21% vs. 59%, p<0.001) and conversely, the portions of those with moderate and severe hyperkalemia significantly decreased (29% vs. 3%, p<0.001; 15% vs, 3%, p<0.001), respectively. Short term treatment of hyperkalemia with oral potassium binder is effective in non-dialysis CKD patients.


Key words: hyperkalemia, potassium binder, CKD, GFR, RAAS therapy.

References

1.De Nicola L, Di Lullo L, Paoletti E, Cupisti A, Bianchi S. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice. J Nephrol. 2018 Oct;31(5):653-664. doi: 10.1007/s40620-018-0502-6. Epub 2018 Jun 7. PMID: 29882199; PMCID: PMC6182350.
2. Muneer K, Nair A. Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies. Indian Heart J. 2017 May-Jun;69(3):371-374. doi: 10.1016/j.ihj.2016.08.007. Epub 2016 Sep 8. PMID: 28648436; PMCID: PMC5485404.
3. Clegg DJ, Headley SA, Germain MJ. Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet. Kidney Med. 2020 Jun 15;2(4):476-487. doi: 10.1016/j.xkme.2020.04.007. PMID: 32775988; PMCID: PMC7406842.
4. Kim GH. Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease. Electrolyte Blood Press. 2019 Jun;17(1):1-6. doi: 10.5049/EBP.2019.17.1.1. Epub 2019 Jun 30. PMID: 31338108; PMCID: PMC6629599.
5. Morales E, Cravedi P, Manrique J. Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options. Front Med (Lausanne). 2021 Jun 4;8:653634. doi: 10.3389/fmed.2021.653634. PMID: 34150795; PMCID: PMC8213200.
6. St-Jules DE, Clegg DJ, Palmer BF, Carrero JJ. Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale. Clin J Am Soc Nephrol. 2022 Mar;17(3):467-472. doi: 10.2215/CJN.09660721. Epub 2021 Oct 20. PMID: 34670798; PMCID: PMC8975039.
7. Valdivielso JM, Carriazo S, Martin M, Fernandez-Fernandez B, Bermudez-López M, Ortiz A; NEFRONA investigators. Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men. Clin Kidney J. 2023 Oct 9;17(1):sfad212. doi: 10.1093/ckj/sfad212. PMID: 38186899; PMCID: PMC10768768.
8. Yu MY, Yeo JH, Park JS, Lee CH, Kim GH. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients. PLoS One. 2017 Mar 22;12(3):e0173542. doi: 10.1371/journal.pone.0173542. PMID: 28328954; PMCID: PMC5362098.
9. Wang X, Chen D, Song X, Wang J, Zhang H. Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3-5 non-dialysis chronic kidney disease: a single-center randomized controlled trial. J Int Med Res. 2023 Apr;51(4):3000605231167516. doi: 10.1177/03000605231167516. PMID: 37063062; PMCID: PMC10119845.
10. Georgianos PI, Liampas I, Kyriakou A, Vaios V, Raptis V, Savvidis N et al. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease. Int Urol Nephrol. 2017 Dec;49(12):2217-2221. doi: 10.1007/s11255-017-1717-5. Epub 2017 Oct 11. PMID: 29027620.
11. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487. Epub 2014 Nov 21. PMID: 25415807.
12. Clegg DJ, Headley SA, Germain MJ. Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet. Kidney Med. 2020 Jun 15;2(4):476-487. doi: 10.1016/j.xkme.2020.04.007. PMID: 32775988; PMCID: PMC7406842.
Published
2024-04-30
How to Cite
SULEJMAN, Sabir et al. SHORT TERM TREATMENT OF CHRONIC HYPERKALEMIA WITH ORAL POTASSIUM BINDER IN CHRONIC KIDNEY DISEASE PATIENTS. Journal of Morphological Sciences, [S.l.], v. 7, n. 1, p. 136-141, apr. 2024. ISSN 2545-4706. Available at: <https://jms.mk/jms/article/view/vol7no1-17>. Date accessed: 20 june 2024.
Section
Articles